An independent intelligence board aggregating credible research, preprints, clinical findings, biohacking experiments, and community discussions on therapeutic peptides, longevity science, and evidence-based anti-aging. Stories are scored for relevance, credibility, novelty, momentum, and practicality so the most important findings surface first.
More prescriptions for semaglutide and tirzepatide were written in the first quarter of 2025, according to recent reporting. In plain terms: doctors are handing out these two weight-loss drugs more often than before. The report summarizes trends in who’s getting them and raises questions about how they’re being used and monitored. Semaglutide and tirzepatide are medicines that copy signals your body already uses to control appetite and blood sugar. Semaglutide is the same active ingredient in brand-name drugs like Ozempic and Wegovy; it mimics a gut hormone that tells your brain you’re full and slows how fast your stomach empties. Tirzepatide (sold as Zepbound or similar names) acts on two related hormone pathways at once, so it can have a bigger effect on appetite and blood sugar. These are not simple diet pills — they are injected medicines that were developed for diabetes and later found to cause significant weight loss in many people. What the reporting and available studies show is that prescription numbers for both drugs rose in Q1 2025, reflecting growing demand. The evidence behind the drugs’ effects comes from clinical trials and real-world use: many people on these medicines lose meaningful weight and often see improved blood sugar control. But the size of the effect varies by person, and most of the strong trial results come from controlled studies with specific dosing and monitoring. The news piece focuses on prescription trends and safety discussions rather than presenting a new clinical trial. It doesn’t claim the drugs are a miracle cure for everyone. This matters because more prescriptions mean more people are using these powerful medicines, for both approved reasons (like diabetes and obesity) and sometimes off-label uses. If you or someone you know is thinking about weight-loss drugs, this trend affects availability, cost, and how doctors manage care. The increase also sparks conversations about who gets access, how long people should stay on the drugs, and how to handle expectations for weight loss versus long-term lifestyle changes. There are important caveats and risks. Common side effects include nausea, diarrhea, and stomach upset; rarer but serious risks involve pancreatitis (pancreas inflammation) and gallbladder problems. These drugs change how your body handles food and blood sugar, so they can interact with other medicines and medical conditions. Long-term safety beyond a few years is still being studied. They require medical supervision: dosing, monitoring for side effects, and decisions about stopping treatment should be made with a clinician. Also, access and cost can be barriers, and not everyone is a candidate for these treatments. Bottom line: prescriptions for semaglutide and tirzepatide are rising, reflecting growing use as effective medical tools for weight and blood-sugar control, but they come with side effects, uncertainties about long-term use, and a need for careful medical oversight.
Source: BusinessWorld Online